Skip to main content
. 2024 Jun 20;20(6):e1011569. doi: 10.1371/journal.ppat.1011569

Fig 1. LALA-PG substitutions eliminate antibody binding to mouse FcγRI, II, III, and IV for both DH1052 and DH1050.1, without altering binding to SARS-CoV-2 Spike.

Fig 1

(A) Antibody engineering schematic depicting wildtype (allotype G1m17) versus Fc-function knockout antibodies (LALA- PG substitutions: L234A, L235A, P329G). NTD-directed non-nAb DH1052 and nAb DH1050.1 are produced in both versions. Color scheme for each antibody is the same throughout A-J. (B) ELISA binding of G1m17 and LALA-PG antibodies to their cognate antigen SARS-CoV-2 Spike_D614G versus negative control antigen HIV-1 envelope. Binding response is measured as area under the log transformed curve (logAUC). Serum from a nonhuman primate vaccinated with NTD was used as the positive control, and CH65 was used as the negative control antibody. (C-F) DH1052 G1m17 versus LALA-PG binding to immobilized mouse FcγRI, II, III, and IV measured via surface plasmon resonance (SPR). (G-J) DH1050.1 G1m17 versus LALA-PG binding to mouse immobilized FcγRI, II, III, and IV measured by SPR.